Medical Device Regulation in Brazil
ANVISA regulates medical devices (Produtos para a Saúde) under RDC 751/2022, which replaced RDC 185/2001. Brazil uses a GHTF-aligned four-class risk-based system. ANVISA is both an IMDRF member and an MDSAP participant, making it one of the more internationally harmonized regulators in Latin America.
Recent Regulatory Updates
Showing the latest 3 updates. Book a demo to see more
IMDRF opens public consultation on supplier control guidance
IMDRF opens consultation on supplier control guidance
Brazil issues guidelines for mobile health units
Sources Tracked by Qalico
Qalico continuously monitors 9 references across guidelines, regulations, and standards for Brazil.
Guidelines
Device Classification
Class I (lowest risk): e.g., bandages, examination gloves. Class II: e.g., needles, syringes. Class III: e.g., ventilators, haemodialysis equipment. Class IV (highest risk): e.g., cardiac stents, implantable pacemakers. Classification follows GHTF/IMDRF rules aligned with international standards.
Official classification guidance →Standards & Key Principles
Applicable Standards
Key Principles
- GHTF/IMDRF-harmonized four-class system
- GMP (Boas Práticas de Fabricação – BPF) certificate mandatory
- Brazilian Authorized Representative required for foreign manufacturers
- Registro (Class III/IV) vs. Cadastro (Class I/II) pathways
- SOLICITA electronic platform for all regulatory submissions
- MDSAP participant: shared audits with FDA, Health Canada, TGA, PMDA
Pre-Market Requirements
Simplified registration via SOLICITA. Declaration of conformity, GMP certificate, labeling review. Faster pathway for lower-risk devices.
Full registration: technical dossier, clinical evidence, GMP Certificate, labeling, risk/benefit analysis submitted to ANVISA.
Mandatory for all device classes. Issued by ANVISA after inspection or via MDSAP audit report. Valid for 2 years.
Post-Market Requirements
Deaths/serious injuries reported to ANVISA via Notivisa system within 7 days; other events within 30 days.
Ongoing monitoring of marketed devices; queixas técnicas and adverse events reported to ANVISA.
ANVISA notified of all voluntary or compulsory recalls; ANVISA can mandate recalls. Notices published publicly.
International Recognition & Reliance
MERCOSUR mutual recognition: devices registered in MERCOSUR countries benefit from harmonized procedures.
MDSAP audit reports accepted by ANVISA, reducing duplicative GMP inspections.